Ex vivo gene therapy with lentiviral vectors (LVs) is an established strategy to treat several genetic blood stem cell diseases. One such example is the gene therapy for metachromatic leukodystrophy (MLD), developed at SR-Tiget and approved in both Europe and the United States.
